Tranzyme Pharma is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, mechanism-based therapeutics to treat upper gastrointestinal motility disorders. Though more than 40 percent of people in the U.S. are affected by these recurring conditions, only a limited number of safe and effective treatment options are available. Through leveraging MATCH, its proprietary drug discovery technology, Tranzyme is dedicated to pursuing first-in-class medicines to address areas with significant unmet medical need. For more information, visit the company’s Web site at www.tranzyme.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: